Scarica l'app Stockscreener
94.88
0.07%
-0.07
Dopo l'orario di chiusura:
94.88
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRUS Giù?
Forum
Previsione
Precedente Chiudi:
$94.95
Aprire:
$94.94
Volume 24 ore:
2.81M
Relative Volume:
1.48
Capitalizzazione di mercato:
$7.18B
Reddito:
$35.93M
Utile/perdita netta:
$-244.56M
Rapporto P/E:
-24.02
EPS:
-3.95
Flusso di cassa netto:
$-157.31M
1 W Prestazione:
+0.32%
1M Prestazione:
+41.82%
6M Prestazione:
+126.39%
1 anno Prestazione:
+81.41%
Intervallo 1D:
$94.75
$94.97
Intervallo di 1 settimana:
$94.33
$95.02
Portata 52W:
$33.19
$95.02
Merus N V Stock (MRUS) Company Profile
Nome
Merus N V
Settore
Industria
Telefono
31 030 253 8800
Indirizzo
YALELAAN 62, 3584 CM UTRECHT
Confronta MRUS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
94.88 | 7.19B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-08-25 | Iniziato | Alliance Global Partners | Buy |
| 2025-02-13 | Iniziato | Piper Sandler | Overweight |
| 2025-02-07 | Iniziato | Wells Fargo | Overweight |
| 2024-11-21 | Iniziato | Goldman | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-03-28 | Iniziato | Truist | Buy |
| 2024-03-04 | Reiterato | Needham | Buy |
| 2023-11-02 | Iniziato | Canaccord Genuity | Buy |
| 2023-08-21 | Iniziato | TD Cowen | Outperform |
| 2022-08-02 | Iniziato | Stifel | Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Needham | Buy |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-06-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-08 | Iniziato | William Blair | Outperform |
| 2021-03-16 | Iniziato | SVB Leerink | Outperform |
| 2020-06-26 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-27 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | Ripresa | Guggenheim | Buy |
| 2019-06-28 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Ripresa | Guggenheim | Buy |
| 2019-04-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | Iniziato | Berenberg | Buy |
| 2018-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-03-21 | Downgrade | Citigroup | Buy → Neutral |
| 2016-12-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2016-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2016-06-13 | Iniziato | Citigroup | Buy |
| 2016-06-13 | Iniziato | Guggenheim | Buy |
| 2016-06-13 | Iniziato | Wedbush | Outperform |
Mostra tutto
Merus N V Borsa (MRUS) Ultime notizie
Will Merus N.V. outperform the marketSwing Trade & Free Weekly Watchlist of Top Performers - newser.com
Will Merus N.V. stock sustain high P E ratiosWeekly Risk Report & Daily Chart Pattern Signals - newser.com
Will Merus N.V. (2GH) stock maintain strong growthBear Alert & Accurate Buy Signal Notifications - newser.com
Why Merus N.V. is moving todayRate Hike & Weekly Setup with ROI Potential - newser.com
Will Merus N.V. stock deliver better than expected guidanceTrade Ideas & AI Powered Market Entry Ideas - newser.com
Can you recover from losses in Merus N.V.July 2025 Levels & Verified Chart Pattern Signals - newser.com
Merus Announces Publication of an Abstract on Petosemtamab - GlobeNewswire
Multi factor analysis applied to Merus N.V.Trade Risk Summary & High Accuracy Trade Alerts - newser.com
Op de AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics kondigt Merus de publicatie aan van het abstract over petosemtamab in gemetastaseerde colorectale kanker - GlobeNewswire Inc.
Merus NV Hits New 52-Week High of $95.02, Up 77.85% - Markets Mojo
Merus NV Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Merus (MRUS) Shares Promising Interim Findings from Phase 2 Canc - GuruFocus
Merus announces initial interim data from phase 2 trial of petosemtamab - TipRanks
Merus reports promising early data for petosemtamab in colorectal cancer By Investing.com - Investing.com Nigeria
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
36 patients: Merus' petosemtamab shows preliminary antitumor activity and manageable safety in mCRC phase 2 - Stock Titan
Will Merus N.V. stock continue upward momentumWeekly Investment Report & Fast Gain Stock Tips - newser.com
Can Merus N.V. stock double in next 5 yearsQuarterly Market Review & Free High Return Stock Watch Alerts - newser.com
Merus Announces Petosemtamab in Metastatic Colorectal - GlobeNewswire
Merus to present petosemtamab data for colorectal cancer at conference By Investing.com - Investing.com Nigeria
Merus N.V. to Present Two Abstracts on Petosemtamab at AACR-NCI-EORTC Conference in Boston - Quiver Quantitative
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
Phase 2 interim data: Merus' petosemtamab to be presented in plenary at AACR Oct 24; poster on cancer stem cells - Stock Titan
Will Merus N.V. price bounce be sustainable2025 Biggest Moves & Daily Stock Trend Watchlist - newser.com
Deals In Depth: September 2025 - insights.citeline.com
Merus (MRUS): Assessing Valuation After Rapid Share Price Gains - Yahoo Finance
Merus N.V. announces proposed public offering of common shares - MSN
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments - MSN
Merus (NASDAQ:MRUS) Hits New 12-Month HighHere's Why - MarketBeat
Merus (NASDAQ:MRUS) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
Automated trading signals detected on Merus N.V.July 2025 Outlook & Low Risk High Win Rate Picks - newser.com
Is Merus N.V. (2GH) stock safe for risk averse investorsWall Street Watch & Accurate Entry/Exit Alerts - newser.com
What margin trends mean for Merus N.V. stockNew Guidance & Daily Price Action Insights - newser.com
Is Merus NV a good long term investmentTrading Psychology Tips & Market Monitoring and Alerts - earlytimes.in
Merus NV stock hits all-time high at 94.56 USD By Investing.com - Investing.com Nigeria
Merus NV stock hits all-time high at 94.56 USD - Investing.com
Will Merus N.V. stock see PE expansion2025 Short Interest & Real-Time Volume Spike Alerts - newser.com
Why Merus N.V. (2GH) stock could outperform next yearJuly 2025 Movers & Reliable Entry Point Alerts - newser.com
Merus’s SWOT analysis: oncology biotech stock faces acquisition, pipeline promise - Investing.com Nigeria
Merus’s SWOT analysis: oncology biotech stock faces acquisition, pipeline promise By Investing.com - Investing.com South Africa
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Inside INdiana Business - FinancialContent
Merus (NASDAQ:MRUS) Downgraded by Leerink Partnrs to "Hold" - MarketBeat
Merus N V Azioni (MRUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Merus N V Azioni (MRUS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Silverman Peter B. | COO & GC |
Jul 17 '25 |
Sale |
60.00 |
25,000 |
1,500,000 |
0 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):